Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35803353)

  • 1. Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England.
    Thomas C; Mandrik O; Whyte S
    Prev Med; 2022 Sep; 162():107131. PubMed ID: 35803353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic Inequalities in Colorectal Cancer Screening in Korea, 2005-2015: After the Introduction of the National Cancer Screening Program.
    Mai TTX; Lee YY; Suh M; Choi E; Lee EY; Ki M; Cho H; Park B; Jun JK; Kim Y; Oh JK; Choi KS
    Yonsei Med J; 2018 Nov; 59(9):1034-1040. PubMed ID: 30328317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decomposing socio-economic inequality in colorectal cancer screening uptake in England.
    Solmi F; Von Wagner C; Kobayashi LC; Raine R; Wardle J; Morris S
    Soc Sci Med; 2015 Jun; 134():76-86. PubMed ID: 25917138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
    Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
    Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.
    De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C
    Value Health; 2018 Jun; 21(6):685-691. PubMed ID: 29909873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.
    Gini A; Meester RGS; Keshavarz H; Oeffinger KC; Ahmed S; Hodgson DC; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2019 Nov; 111(11):1161-1169. PubMed ID: 30980665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Earlier or More Intensive Colorectal Cancer Screening in Overweight and Obese Patients.
    Yeoh A; Mannalithara A; Ladabaum U
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):507-519. PubMed ID: 35940514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.
    Cross AJ; Robbins EC; Pack K; Stenson I; Kirby PL; Patel B; Rutter MD; Veitch AM; Saunders BP; Little M; Gray A; Duffy SW; Wooldrage K
    Health Technol Assess; 2022 May; 26(26):1-156. PubMed ID: 35635015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 15. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
    Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
    Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.